CUFinder

Jake Chabon

Jake Chabon

Stanford University

H-index: 27

North America-United States

Contact Jake Chabon

About Jake Chabon

Jake Chabon, With an exceptional h-index of 27 and a recent h-index of 25 (since 2020), a distinguished researcher at Stanford University, specializes in the field of ctDNA, cell free DNA, Genomics, Cancer Biology, Bioinformatics.

His recent articles reflect a diverse array of research interests and contributions to the field:

Methods and Systems for Analyzing Nucleic Acid Molecules

Quantification of Cerebrospinal Fluid Tumor DNA in Lung Cancer Patients with Suspected Leptomeningeal Carcinomatosis

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy

Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

Phased Variants Allow Robust Profiling of Circulating Tumor DNA in Untreated Follicular Lymphomas

Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study

Systems and Methods for Protecting Nucleic Acid Molecules

Jake Chabon Information

University

Position

Postdoctoral Fellow School of Medicine

Citations(all)

6326

Citations(since 2020)

5310

Cited By

2825

hIndex(all)

27

hIndex(since 2020)

25

i10Index(all)

39

i10Index(since 2020)

34

Email

University Profile Page

Google Scholar

Jake Chabon Skills & Research Interests

ctDNA

cell free DNA

Genomics

Cancer Biology

Bioinformatics

Top articles of Jake Chabon

Methods and Systems for Analyzing Nucleic Acid Molecules

2024/4/9

Quantification of Cerebrospinal Fluid Tumor DNA in Lung Cancer Patients with Suspected Leptomeningeal Carcinomatosis

medRxiv

2024

David Merriott
David Merriott

H-Index: 5

Christopher Yoo
Christopher Yoo

H-Index: 20

Emily Chen
Emily Chen

H-Index: 4

Aaron M Newman
Aaron M Newman

H-Index: 31

Michael Iv
Michael Iv

H-Index: 14

Melanie Hayden Gephart
Melanie Hayden Gephart

H-Index: 19

Maximilian Diehn
Maximilian Diehn

H-Index: 51

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy

Blood

2023/11/28

Jordan Goldstein
Jordan Goldstein

H-Index: 3

Sang Eun Yoon
Sang Eun Yoon

H-Index: 3

Seok Jin Kim
Seok Jin Kim

H-Index: 33

Ryan C Lynch
Ryan C Lynch

H-Index: 15

Davide Rossi
Davide Rossi

H-Index: 27

Maximilian Diehn
Maximilian Diehn

H-Index: 51

Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood

2023/11/28

Ying Wang
Ying Wang

H-Index: 3

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

Blood

2023/11/28

Ethan Thompson
Ethan Thompson

H-Index: 1

Manali Kamdar
Manali Kamdar

H-Index: 16

Phased Variants Allow Robust Profiling of Circulating Tumor DNA in Untreated Follicular Lymphomas

Blood

2023/11/28

Ákos Nagy
Ákos Nagy

H-Index: 3

Maximilian Diehn
Maximilian Diehn

H-Index: 51

Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study

Blood

2023/11/28

Sang Eun Yoon
Sang Eun Yoon

H-Index: 3

Seok Jin Kim
Seok Jin Kim

H-Index: 33

Maximilian Diehn
Maximilian Diehn

H-Index: 51

Systems and Methods for Protecting Nucleic Acid Molecules

2023/8/3

Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas

Blood Advances

2023/6/13

Ryan C Lynch
Ryan C Lynch

H-Index: 15

Christina Poh
Christina Poh

H-Index: 3

Heather Rasmussen
Heather Rasmussen

H-Index: 9

MRD‐negativity after frontline DLBCL therapy: pooled analysis of 6 clinical trials

Hematological Oncology

2023/6

Combined autologous CD30. CAR‐T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study)

Hematological Oncology

2023/6

Ultrasensitive ctDNA minimal residual disease monitoring in early NSCLC with PhasED-Seq

Cancer Research

2023/4/4

David R Jones
David R Jones

H-Index: 3

Daniel Gomez
Daniel Gomez

H-Index: 13

Andres Martinez
Andres Martinez

H-Index: 2

Maximilian Diehn
Maximilian Diehn

H-Index: 51

MRD-negativity as a potential surrogate endpoint after frontline DLBCL therapy: pooled analysis of trials & implications for clinical trial design

Blood

2022/11/15

Ryan C Lynch
Ryan C Lynch

H-Index: 15

Charles Macaulay
Charles Macaulay

H-Index: 4

Davide Rossi
Davide Rossi

H-Index: 27

Maximilian Diehn
Maximilian Diehn

H-Index: 51

Ultrasensitive MRD profiling predicts outcomes in DLBCL after frontline therapy with tafasitamab in combination with lenalidomide and R-CHOP

Blood

2022/11/15

Maximilian Diehn
Maximilian Diehn

H-Index: 51

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30. CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

Blood

2022/11/15

Genomic profiling of bronchoalveolar lavage fluid in lung cancer

Cancer research

2022/8/16

Li Zhou
Li Zhou

H-Index: 6

Jalen Benson
Jalen Benson

H-Index: 7

Natalie Lui
Natalie Lui

H-Index: 11

Mark Berry
Mark Berry

H-Index: 5

Maximilian Diehn
Maximilian Diehn

H-Index: 51

Inferring gene expression from cell-free DNA fragmentation profiles

Nature biotechnology

2022/4

Mohammad Shahrokh Esfahani
Mohammad Shahrokh Esfahani

H-Index: 18

Joanne Soo
Joanne Soo

H-Index: 5

Binbin Chen
Binbin Chen

H-Index: 11

Aaron M Newman
Aaron M Newman

H-Index: 31

Maximilian Diehn
Maximilian Diehn

H-Index: 51

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

Nature biotechnology

2021/12

Joanne Soo
Joanne Soo

H-Index: 5

Florian Scherer
Florian Scherer

H-Index: 13

Binbin Chen
Binbin Chen

H-Index: 11

Davide Rossi
Davide Rossi

H-Index: 27

Maximilian Diehn
Maximilian Diehn

H-Index: 51

Phase 2 study of acalabrutinib window prior to frontline therapy in untreated aggressive B-cell lymphoma: Preliminary results and correlatives of response to acalabrutinib

Blood

2021/11/23

Amynah Pradhan
Amynah Pradhan

H-Index: 20

Yandan Yang
Yandan Yang

H-Index: 2

A comprehensive circulating tumor DNA assay for detection of translocation and copy-number changes in pediatric sarcomas

Molecular cancer therapeutics

2021/10/1

Maximilian Diehn
Maximilian Diehn

H-Index: 51

See List of Professors in Jake Chabon University(Stanford University)

Co-Authors

academic-engine

Useful Links

List of top 50 universities
List of top 100 universities
List of top 500 universities
Find Professors Email
Find Universities Email
CUFinder Academic Engine